A SURVEY OF RHEUMATOLOGY PATIENTS' SATISFACTION TO SWITCHING FROM ORIGINATOR TO BIOSIMILAR AGENTS

被引：0
|
作者：
Ng, C. R. [1 ]
Samec, S. [1 ]
Kavanagh, P. [1 ]
Mccarthy, G. [1 ]
Donnelly, S. [1 ]
Wilson, A. G. [1 ]
机构：
[1] Mater Misericordiae Univ Hosp, Dept Rheumatol, Dublin, Ireland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.2981
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0805
引用
收藏
页码：1427 / 1427
页数：1
相关论文
共 50 条
  • [1] THE RESOURCE COST OF SWITCHING STABLE RHEUMATOLOGY PATIENTS FROM AN ORIGINATOR BIOLOGIC TO A BIOSIMILAR IN THE UK
    Barnes, T.
    Wong, E.
    Thakrar, K.
    Glen, F.
    Young-Min, S.
    Marchbank, K.
    Ingram, A.
    VALUE IN HEALTH, 2017, 20 (09) : A543 - A543
  • [2] SWITCHING STABLE RHEUMATOLOGY PATIENTS FROM AN ORIGINATOR BIOLOGIC TO A BIOSIMILAR: RESOURCE COST IN THE UK
    Barnes, Theresa
    Wong, Ernest
    Thakrar, Kashyap
    Douglas, Karen
    Glen, Fiona
    Young-Min, Steven
    Marchbank, Katie
    Ingram, Andy
    RHEUMATOLOGY, 2018, 57
  • [3] Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis
    Nielsen, Valdemar Wendelboe
    Lund, Tamara Theresia
    Gniadecki, Robert
    Olsen, Rasmus Huan
    Nissen, Christoffer Valdemar
    Schwensen, Jakob Ferlov Baselius
    Thomsen, Simon Francis
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [4] COST OF SWITCHING FROM AN ORIGINATOR BIOLOGIC (REMICADE) TO A BIOSIMILAR
    Brown, C. N.
    McCann, E.
    VALUE IN HEALTH, 2016, 19 (07) : A581 - A581
  • [5] Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
    Montero-Vilchez, Trinidad
    Cuenca-Barrales, Carlos
    Rodriguez-Tejero, Andrea
    Martinez-Lopez, Antonio
    Arias-Santiago, Salvador
    Molina-Leyva, Alejandro
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (04)
  • [6] Switching from adalimumab originator to biosimilar: clinical experience in hidradenitis suppurativa patients
    Montero-Vilchez, Trinidad
    Rodriguez-Tejero, Andrea
    Sanchez-Diaz, Manuel
    Arias-Santiago, Salvador
    Molina-Leyva, Alejandro
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 80 - 80
  • [7] Dosing Penalty of Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable Hemodialysis Patients
    Minutolo, Roberto
    Borzumati, Maurizio
    Sposini, Stefano
    Abaterusso, Cataldo
    Carraro, Gianni
    Santoboni, Alberto
    Mura, Carlo
    Filiberti, Oliviero
    Santoro, Domenico
    Musacchio, Romano
    Imperiali, Patrizio
    Fiorini, Fulvio
    De Nicola, Luca
    Russo, Domenico
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 68 (01) : 170 - 172
  • [8] ASSESSING REASONS FOR PATIENTS SWITCHING BACK FROM BIOSIMILAR ETANERCEPT THERAPY TO ORIGINATOR PRODUCT
    Dahanayake, Chanaka
    Shah, Kavina
    Al-Abdulla, Ahmad
    Carulli, Maresa
    RHEUMATOLOGY, 2019, 58
  • [9] Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease
    Casanova, M. J.
    Chaparro, M.
    Nantes, O.
    Varela, P.
    Vela-Gonzalez, M.
    Montserrat, R.
    Sierra, O. G.
    Riestra, S.
    Barreiro-de Acosta, M.
    Martin-Rodriguez, M. M.
    Gargallo-Puyuelo, C. J.
    Reygosa, C.
    Munoz, R.
    Garcia de la Filia-Molina, I.
    Nunez-Ortiz, A.
    Kolle, L.
    Calafat, M.
    Huguet, J. M.
    Iglesias-Flores, E.
    Martinez-Perez, T. J.
    Bosch, O.
    Duque-Alcorta, J. M.
    Frago-Larramona, S.
    Sanchez-Azofra, M.
    Van Domselaar, M.
    Gonzalez-Cosano, V. M.
    Bujanda, L.
    Rubio, S.
    Mancebo, A.
    Castro, B.
    Garcia-Lopez, S.
    de Francisco, R.
    Nieto, L.
    Laredo, V.
    Gutierrez, A.
    Mesonero, F.
    Leo-Carnerero, E.
    Canete, F.
    Ruiz, L.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I474 - I475
  • [10] Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab
    Srinivasan, Ashish
    Haifer, Craig
    Thin, Lena
    MEDICAL JOURNAL OF AUSTRALIA, 2021, 215 (09) : 435 - 435
12345